Disclosures: Leeor Hershkovich: Nothing to Disclose, Harel Dahari: Nothing to Disclose, Scott Cotler: Nothing to Disclose, Theo Heller: Nothing to Disclose, Christopher Koh: Nothing to Disclose, Jeffrey Glenn: Nothing to Disclose, Tarik Asselah: Nothing to Disclose, Saeed Hamid: Nothing to Disclose, Ohad Etzion: Nothing to Disclose 428 HIGHER SUSTAINED RESPONSE RATE AND PARTIAL CURE IN NUC EXPERIENCED PEGYLATED INTERFERON-TREATED PATIENTS COMPARED TO NUC NAÏVE PEGYLATED INTERFERON MONOTHERAPY PATIENTS Rachel Wen-Juei Jeng 1 Yu-Ting Kao 2 Yen-Chun Liu 2 Rong-Nan Chien 2 , 1 Chang Gung Medical Foundation, 2 Chang Gung Memorial Hospital, Linkou Medical Center, Taiwan Background: Our previous study showed that patients with off-Nuc clinical relapse (CR) retreated with pegylated interferon (Peg-IFN) also had a higher functional cure rate than NUC-nave Peg-IFN patients (10-year: 49.2% vs

Natural products for Gut-X axis: Pharmacology, toxicology and microbiology in mycotoxin-caused diseases
The total testing cost per Medicaid beneficiary was $187.70 for SOC vs
Puia-DumitrescuMComstockBALiSHeagertyPJPerezKMLawJBet alAssessment of 2-year neurodevelopmental outcomes in extremely preterm infants receiving opioids and benzodiazepines
doi: 10.1016/j.immuni.2015.11.024 200 SprootenJLaureanoRSVanmeerbeekIGovaertsJNaulaertsSBorrasDMet al